We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Risk of secondary cancers from scattered radiation during intensity-modulated radiotherapies for hepatocellular carcinoma.
- Authors
Kim, Dong Wook; Chung, Kwangzoo; Chung, Weon Kuu; Bae, Sun Hyun; Shin, Dong Oh; Hong, Seongeon; Park, Sung Ho; Park, Sung-Yong; Hong, Chae-Seon; Lim, Young Kyung; Shin, Dongho; Lee, Se Byeong; Lee, Hyun-Ho; Sung, Jiwon; Yoon, Myonggeun
- Abstract
<bold>Purpose: </bold>To evaluate and compare the risks of secondary cancers from therapeutic doses received by patients with hepatocellular carcinoma (HCC) during intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT), and tomotherapy (TOMO).<bold>Methods: </bold>Treatments for five patients with hepatocellular carcinoma (HCC) were planned using IMRT, VMAT, and TOMO. Based on the Biological Effects of Ionizing Radiation VII method, the excess relative risk (ERR), excess absolute risk (EAR), and lifetime attributable risk (LAR) were evaluated from therapeutic doses, which were measured using radiophotoluminescence glass dosimeters (RPLGDs) for each organ inside a humanoid phantom.<bold>Results: </bold>The average organ equivalent doses (OEDs) of 5 patients were measured as 0.23, 1.18, 0.91, 0.95, 0.97, 0.24, and 0.20 Gy for the thyroid, lung, stomach, liver, small intestine, prostate (or ovary), and rectum, respectively. From the OED measurements, LAR incidence were calculated as 83, 46, 22, 30, 2 and 6 per 10(4) person for the lung, stomach, normal liver, small intestine, prostate (or ovary), and rectum.<bold>Conclusions: </bold>We estimated the secondary cancer risks at various organs for patients with HCC who received different treatment modalities. We found that HCC treatment is associated with a high secondary cancer risk in the lung and stomach.
- Publication
Radiation Oncology, 2014, Vol 9, Issue 1, p109
- ISSN
1748-717X
- Publication type
journal article
- DOI
10.1186/1748-717X-9-109